Sugi Predict

Sugi Predict / Compounds / SCHEMBL402719

SCHEMBL402719

SCHEMBL402719

Cc1ccc(NC(=O)Nc2cc(F)cc(CN(C)S(=O)(=O)N(C)C)c2)cn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KCNQ3 O43525 1/20 0.43
▸ KCNQ2 O43526 1/20 0.43
▸ MAPK10 P53779 5/20 0.42
▸ NAMPT P43490 5/20 0.42
▸ MAPK8 P45983 4/20 0.42
▸ NPSR1 Q6W5P4 2/20 0.41
▸ KCNJ6 P48051 1/20 0.40
▸ KCNJ5 P48544 1/20 0.40
▸ KCNJ3 P48549 1/20 0.40
▸ CYP1A2 P05177 1/20 0.39
▸ DDX3X O00571 1/20 0.38
▸ SMN1; SMN2 Q16637 3/20 0.37
▸ NPC1 O15118 2/20 0.37
▸ RAB9A P51151 2/20 0.37
▸ MAPK9 P45984 1/20 0.37
▸ MEN1 O00255 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ PABPC1 P11940 1/20 0.37
▸ TP53 P04637 1/20 0.37
▸ LMNA P02545 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29714031 0.90 DDX3X (0.42) KCNQ3KCNQ2MAPK10NAMPTMAPK8
SCHEMBL398554 0.90 DDX3X (0.42) KCNQ3KCNQ2MAPK10NAMPTMAPK8
SCHEMBL402899 0.85 TAAR1 (0.54) NAMPTCYP1A2NPC1RAB9AMEN1
SCHEMBL1446068 0.83 HRH3 (0.45) KCNQ3KCNQ2MAPK10MAPK8NPSR1
SCHEMBL402720 0.82 NPSR1 (0.40) KCNQ3KCNQ2MAPK10NAMPTMAPK8
SCHEMBL1447081 0.81 CYP1A2 (0.42) KCNQ3KCNQ2MAPK10NAMPTMAPK8
SCHEMBL402721 0.79 CYP1A2 (0.44) KCNQ3KCNQ2MAPK10MAPK8CYP1A2
SCHEMBL3211164 0.79 NPSR1 (0.47) KCNQ3KCNQ2MAPK10NAMPTMAPK8
SCHEMBL3211160 0.78 NPSR1 (0.46) KCNQ3KCNQ2MAPK10MAPK8NPSR1
SCHEMBL401393 0.78 CYP1A2 (0.48) MAPK10NAMPTMAPK8CYP1A2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210198203-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2021-07-01 — — US claimed
US-10385023-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2019-08-20 — — US claimed
US-20150005296-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2015-01-01 — — US claimed
EP-1765327-A4 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS INC (US) 2009-06-17 — — EP claimed
US-20090036447-A1 Compounds, Compositions and Methods CYTOKINETICS, INC. (US) 2009-02-05 — — US claimed
EP-1765327-A2 COMPOUNDS, COMPOSITIONS AND METHODS Cytokinetics, Inc. (US) 2007-03-28 — — EP claimed
WO-2006009726-A2 SUBSTITUTED UREA DERIVATIVES FOR TREATING CARDIAC DISEASES CYTOKINETICS, INC. (US) 2006-01-26 — — WO claimed
US-20060014761-A1 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate CYTOKINETICS, INCORPORATED 2006-01-19 — — US claimed
US-12264133-B2 Compounds, compositions and methods CYTOKINETICS, INCORPORATED (US) 2025-04-01 — — US disclosed
US-20220185779-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2022-06-16 — — US disclosed
US-20210198203-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2021-07-01 — — US disclosed
US-10975034-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2021-04-13 — — US disclosed
US-20190352267-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2019-11-21 — — US disclosed
US-10385023-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2019-08-20 — — US disclosed
US-20070208000-A1 Certain chemical entities, compositions and methods CYTOKINETICS, INC. 2007-09-06 — — US disclosed
US-20070197505-A1 Certain chemical entities, compositions and methods CYTOKINETICS, INC. 2007-08-23 — — US disclosed
US-20070161617-A1 Certain chemical entities, compositions and methods CYTOKINETICS, INC. 2007-07-12 — — US disclosed
EP-1765327-A2 COMPOUNDS, COMPOSITIONS AND METHODS Cytokinetics, Inc. (US) 2007-03-28 — — EP disclosed
WO-2006009726-A2 SUBSTITUTED UREA DERIVATIVES FOR TREATING CARDIAC DISEASES CYTOKINETICS, INC. (US) 2006-01-26 — — WO disclosed
US-20060014761-A1 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate CYTOKINETICS, INCORPORATED 2006-01-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161617-A1 Certain chemical entities, compositions and methods TNNI3, TNNT2, MYLK2 KCNQ3 3060/4885KCNQ2 2435/4885MAPK10 2458/4885
US-20060014761-A1 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate TNNI3, MYLK2, TNNT2 KCNQ3 3612/4885KCNQ2 3389/4885MAPK10 1989/4885
US-10385023-B2 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 KCNQ3 3001/4885KCNQ2 2819/4885MAPK10 2521/4885
US-20220185779-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 KCNQ3 3001/4885KCNQ2 2819/4885MAPK10 2521/4885
US-12264133-B2 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 KCNQ3 3001/4885KCNQ2 2819/4885MAPK10 2521/4885
US-20190352267-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 KCNQ3 3001/4885KCNQ2 2819/4885MAPK10 2521/4885
US-20070208000-A1 Certain chemical entities, compositions and methods TNNI3, TNNT2, MYLK2 KCNQ3 3060/4885KCNQ2 2435/4885MAPK10 2458/4885
US-20070197505-A1 Certain chemical entities, compositions and methods TNNC1, TNNI3, TNNT2 KCNQ3 4642/4885KCNQ2 4428/4885MAPK10 2706/4885
US-20150005296-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 KCNQ3 3001/4885KCNQ2 2819/4885MAPK10 2521/4885
US-10975034-B2 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 KCNQ3 3001/4885KCNQ2 2819/4885MAPK10 2521/4885
US-20090036447-A1 Compounds, Compositions and Methods TNNI3, TNNC1, TNNT2 KCNQ3 3001/4885KCNQ2 2819/4885MAPK10 2521/4885
US-20210198203-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 KCNQ3 3001/4885KCNQ2 2819/4885MAPK10 2521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.